BI Asset Management Fondsmaeglerselskab A S Grows Holdings in DexCom, Inc. $DXCM

BI Asset Management Fondsmaeglerselskab A S grew its position in DexCom, Inc. (NASDAQ:DXCM) by 22.9% in the fourth quarter, HoldingsChannel reports. The fund owned 67,458 shares of the medical device company’s stock after acquiring an additional 12,578 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in DexCom were worth $4,477,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Gradient Investments LLC raised its holdings in DexCom by 13.8% during the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after buying an additional 40,343 shares during the period. Nordea Investment Management AB boosted its holdings in shares of DexCom by 118.6% in the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after buying an additional 137,986 shares during the period. NEOS Investment Management LLC boosted its holdings in shares of DexCom by 58.7% in the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after buying an additional 65,066 shares during the period. Banco Santander S.A. increased its position in shares of DexCom by 28.9% during the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock worth $16,843,000 after acquiring an additional 56,062 shares in the last quarter. Finally, Banque Pictet & Cie SA increased its position in shares of DexCom by 58.2% during the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after acquiring an additional 40,411 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $72.86 on Monday. The company has a market cap of $28.11 billion, a PE ratio of 31.14, a PEG ratio of 1.14 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a 50 day moving average of $64.83 and a 200-day moving average of $67.04.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares in the company, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 42,694 shares of company stock worth $3,029,267. Insiders own 0.28% of the company’s stock.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Analyst Ratings Changes

Several analysts have issued reports on DXCM shares. Benchmark started coverage on DexCom in a research note on Monday, May 11th. They issued a “buy” rating and a $77.00 price target on the stock. Robert W. Baird set a $80.00 price objective on DexCom in a research report on Friday, May 1st. BTIG Research reissued a “buy” rating and issued a $85.00 target price on shares of DexCom in a research report on Monday, March 9th. Mizuho set a $75.00 target price on DexCom in a research note on Friday, May 1st. Finally, Bank of America reduced their price target on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.63.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.